Cardiff Oncology

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cardiff Oncology reports strong Q3 performance and strategic growth plans

Cardiff Oncology's Q3 2023 performance reflects strong progress with positive data from their lead program and promising efficacy of onvansertib, supported by a solid financial position.
While the company faces challenges in maintaining clinical trial progress and managing expenses, strategic strengths like the expanded partnership with Pfizer and focus on shareholder value creation position them well for future growth.
Opportunities lie in advancing their lead program, exploring new therapeutic indications, and leveraging collaborations to drive market penetration and enhance competitiveness in the oncology space.

Cardiff Oncology reports strong Q4 performance and strategic advancements

Cardiff Oncology's Q4 2023 earnings call highlighted a strategic shift in their mCRC program, positive clinical data from the ONSEMBLE trial, and a strong financial position. While facing challenges in addressing various analyst inquiries, the company is well-positioned to capitalize on opportunities in expanding their treatment portfolio and leveraging trial data for market differentiation.

Cardiff Oncology reports positive data and strong financial position

Cardiff Oncology's Q1 2024 earnings call highlighted positive data on onvansertib, ongoing trials, and a healthy financial position. Challenges include trial enrollment pace and follow-up data requirements. However, the company has opportunities for growth through successful trials and leveraging preclinical data.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, March 1, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a panel discussion and one-on-one investor meetings at Cowen's 42nd Annual Healthcare Conference taking place virtually March 7-9, 2022.   Details on the panel can be found below.

Cardiff Oncology to Participate in Cowen's 42nd Annual Healthcare Conference

SAN DIEGO, Feb. 24, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced recent company highlights and financial results from the fourth quarter and full year ended December 31, 2021. "Our recent progress has provided additional clinical and external validation of onvansertib, including a Pfizer Breakthrough Growth Initiative collaboration," said Mark Erlander, Ph.D.

Cardiff Oncology Reports Fourth Quarter and Full Year 2021 Results and Recent Highlights

Cardiff Oncology (CRDF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardiff Oncology (CRDF) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

SAN DIEGO, Jan. 20, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that company management will present and participate in one-on-one meetings at the B. Riley Securities 2022 Oncology Conference, taking place virtually January 27 – 28, 2022.

Cardiff Oncology to Present at the B. Riley Securities 2022 Oncology Conference

Leap Therapeutics

These clinical-stage biotech stocks are headed in opposite directions today.

These 2 Nasdaq Stocks Are Poised to Make Big Moves Today

Cardiff Oncology Inc (NASDAQ: CRDF) posted new data from Phase 1b/2 trial of onvansertib combined with standard-of-care (SOC) FOLFIRI/bevacizumab for second-line KRAS-mutated metastatic colorectal cancer (mCRC). The data will be shared at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

Cardiff Oncology Slumps On New Data From Lead Program In Metastatic Colorectal Cancer

SAN DIEGO, Jan. 18, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced new data from its lead clinical program evaluating onvansertib in combination with standard-of-care (SOC) FOLFIRI/bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). A subset of these data will be featured in a poster presented by Dr. Heinz-Josef Lenz, principal investigator, USC Norris Comprehensive Cancer Center, at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCOGI) on Saturday, January 22, 2022.

Cardiff Oncology Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival

SAN DIEGO, Jan. 11, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced the appointments of Tod Smeal, Ph.D., as chief scientific officer (CSO) and Charles Monahan, RPh, as senior vice president, regulatory affairs.

Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice President, Regulatory Affairs

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that it will be hosting a conference call and webcast to discuss updated data from its lead clinical program in KRAS-mutated metastatic colorectal cancer on Tuesday, January 18, 2022, at 5:00 PM ET. Details on the conference call and webcast can be found below.

Cardiff Oncology to Host Conference Call and Webcast to Discuss Updated Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Being Presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Aurinia Pharmaceuticals

Axsome Therapeutics

These three stocks are poised for a major breakout in 2022.

My 3 Top Biopharma Stock Picks for 2022

SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that company management will present at the H.C. Wainwright BioConnect Virtual Conference, taking place January 10 – 13, 2022.

Cardiff Oncology to Present at the H.C. Wainwright BioConnect Virtual Conference

Cardiff has one asset, onvansertib, a PLK1 inhibitor which has performed well in the clinic thus far in second line KRAS-mutated mCRC.

Cardiff: The Pfizer Interest Is Interesting

TechnipFMC

Patterson-UTI Energy

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 ‘Strong Buy' Stocks Trading Under $10 With Huge Upside Potential

SAN DIEGO, Dec. 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that updated data from its lead KRAS-mutated metastatic colorectal cancer program will be featured in a poster presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI). ASCO-GI is taking place January 20-22, 2022, both virtually and in-person at the Moscone West Building in San Francisco, California.

Cardiff Oncology Announces Upcoming Presentation on Lead KRAS-mutated Metastatic Colorectal Cancer Program at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

SAN DIEGO, Dec. 3, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that on December 2, 2021, non-qualified stock option awards to purchase an aggregate of 200,112 shares of its common stock were granted to two new employees. The stock options were granted as inducements material to the new employees becoming employees of Cardiff Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).

Cardiff Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cardiff Oncology is a prime takeover target heading into 2022.

1 Cancer Stock on Buyout Watch in 2022

The clinical-stage oncology specialist is getting an infusion of cash from pharmaceutical giant Pfizer.

Why Cardiff Oncology Shares Were Up More Than 15% on Thursday

Pfizer Inc (NYSE: PFE) has made a $15 million equity investment in Cardiff Oncology Inc (NASDAQ: CRDF) as part of the Pfizer Breakthrough Growth Initiative. Pfizer purchased 2.4 million shares of Cardiff Oncology's shares at $6.22 per share.

Cardiff Oncology Stock Rises After $15M Equity Investment From Pfizer

The stock price of Cardiff Oncology Inc (NASDAQ: CRDF) increased by over 19% pre-market today. This is why it happened.

Cardiff Oncology (CRDF) Stock: Why The Price Jumped Today

Pfizer

SAN DIEGO, Nov. 18, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need (including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resistant prostate cancer), today announced that Pfizer Inc. (NYSE: PFE) has made a $15 million equity investment in the company as part of the Pfizer Breakthrough Growth Initiative, a program focused on funding innovative science to meet patient needs. Pursuant to a securities purchase agreement between the parties, Pfizer purchased 2.4 million shares of Cardiff Oncology's common stock at a price of $6.22 per share.

Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative

SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that company management will present and participate in virtual 1x1 investor meetings at the Jefferies London Healthcare Conference and the Piper Sandler 33rd Annual Healthcare Conference, taking place November 16 – 19, 2021, and November 29 – December 2, 2021, respectively. Details on the presentations can be found below.

Cardiff Oncology to Present at Upcoming Jefferies London Healthcare and Piper Sandler 33rd Annual Investor Conferences

SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced recent company highlights and financial results for the third quarter ended September 30, 2021.  "During the third quarter, the data we released from our Phase 1b/2 KRAS-mutated metastatic colorectal cancer trial showed meaningful improvements in treatment response and durability relative to historical controls," said Mark Erlander, Ph.D.

Cardiff Oncology Reports Third Quarter 2021 Results and Provides Business Updates

Will Cardiff Oncology (CRDF) Report Negative Q3 Earnings? What You Should Know

CRDF's onvansertib has better data than both Amgen and Mirati in colorectal cancer.

Cardiff Oncology: A High Risk-Reward Opportunity In KRAS-Mutated Cancers

Cardiff Oncology (CRDF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

News for Cardiff Oncology Stock (CRDF)